Taeho Greg Rhee1,2, Yookyung Christy Choi3, Gregory M Ouellet1, Joseph S Ross2,4,5. 1. Section of Geriatrics, Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut. 2. Center for Outcomes Research and Evaluation, Yale-New Haven Health System, New Haven, Connecticut. 3. Department of Pharmaceutical Care and Health Systems, College of Pharmacy, University of Minnesota, Minneapolis, MN. 4. Section of General Internal Medicine, Department of Internal Medicine, School of Medicine, Yale University, New Haven, Connecticut. 5. Department of Health Policy and Management, School of Public Health, Yale University, New Haven, Connecticut.
Abstract
OBJECTIVES: To estimate prescribing tends of and correlates independently associated with high-risk anticholinergic prescriptions in adults aged 65 and older in office-based outpatient visits. DESIGN: Repeated cross-sectional analysis. SETTING: National Ambulatory Medical Care Survey (NAMCS). PARTICIPANTS: A national sample of office-based physician visits by adults aged 65 and older from 2006 to 2015 (n=96,996 unweighted). MEASUREMENTS: Prescriptions of high-risk anticholinergics, regardless of indication, were identified, and overall prescribing trends were estimated from 2006 to 2015. Stratified analyses of prescribing trends according to physician specialty and anticholinergic drug class were also performed. We used a multivariable logistic regression analysis to estimate the odds of high-risk anticholinergic prescription. RESULTS: Between 2006 and 2015, a high-risk anticholinergic prescription was listed for 5,876 (6.2%) 96,996 visits of older adults, representative of 14.6 million total visits nationally. The most common drug classes were antidepressants, antimuscarinics, and antihistamines, which accounted for more than 70% of prescribed anticholinergics. Correlates independently associated with greater odds of receiving a high-risk anticholinergic prescription were female sex, the Southern geographic region, specific physician specialties (e.g., psychiatry, urology), receipt of 6 or more concomitantly prescribed medications, and related clinical diagnoses (e.g., urinary continence) (p<.01 for all). CONCLUSION: The prevalence of high-risk anticholinergic prescriptions was stable over time but varied according to physician specialty and drug class. Quality prescribing should be promoted because safer alternatives are available.
OBJECTIVES: To estimate prescribing tends of and correlates independently associated with high-risk anticholinergic prescriptions in adults aged 65 and older in office-based outpatient visits. DESIGN: Repeated cross-sectional analysis. SETTING: National Ambulatory Medical Care Survey (NAMCS). PARTICIPANTS: A national sample of office-based physician visits by adults aged 65 and older from 2006 to 2015 (n=96,996 unweighted). MEASUREMENTS: Prescriptions of high-risk anticholinergics, regardless of indication, were identified, and overall prescribing trends were estimated from 2006 to 2015. Stratified analyses of prescribing trends according to physician specialty and anticholinergic drug class were also performed. We used a multivariable logistic regression analysis to estimate the odds of high-risk anticholinergic prescription. RESULTS: Between 2006 and 2015, a high-risk anticholinergic prescription was listed for 5,876 (6.2%) 96,996 visits of older adults, representative of 14.6 million total visits nationally. The most common drug classes were antidepressants, antimuscarinics, and antihistamines, which accounted for more than 70% of prescribed anticholinergics. Correlates independently associated with greater odds of receiving a high-risk anticholinergic prescription were female sex, the Southern geographic region, specific physician specialties (e.g., psychiatry, urology), receipt of 6 or more concomitantly prescribed medications, and related clinical diagnoses (e.g., urinary continence) (p<.01 for all). CONCLUSION: The prevalence of high-risk anticholinergic prescriptions was stable over time but varied according to physician specialty and drug class. Quality prescribing should be promoted because safer alternatives are available.
Authors: Shannon L Risacher; Brenna C McDonald; Eileen F Tallman; John D West; Martin R Farlow; Fredrick W Unverzagt; Sujuan Gao; Malaz Boustani; Paul K Crane; Ronald C Petersen; Clifford R Jack; William J Jagust; Paul S Aisen; Michael W Weiner; Andrew J Saykin Journal: JAMA Neurol Date: 2016-06-01 Impact factor: 18.302
Authors: Taeho Greg Rhee; Benjamin D Capistrant; Jon C Schommer; Ronald S Hadsall; Donald L Uden Journal: Prev Med Date: 2017-04-14 Impact factor: 4.018
Authors: Sandipan Bhattacharjee; Jeannie K Lee; Asad E Patanwala; Nina Vadiei; Daniel C Malone; Shannon M Knapp; Wei-Hsuan Lo-Ciganic; William J Burke Journal: Am J Geriatr Psychiatry Date: 2019-02-07 Impact factor: 4.105
Authors: I Cenzer; N Nkansah-Mahaney; M Wehner; M M Chren; T Berger; K Covinsky; K Berger; K Abuabara; E Linos Journal: Br J Dermatol Date: 2019-07-21 Impact factor: 9.302
Authors: Shahar Shmuel; Virginia Pate; Marc J Pepin; Janine C Bailey; Laura C Hanson; Til Stürmer; Rebecca B Naumann; Yvonne M Golightly; Danijela Gnjidic; Jennifer L Lund Journal: Pharmacoepidemiol Drug Saf Date: 2020-10-15 Impact factor: 2.890